RU2013130002A - Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками - Google Patents

Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками Download PDF

Info

Publication number
RU2013130002A
RU2013130002A RU2013130002/10A RU2013130002A RU2013130002A RU 2013130002 A RU2013130002 A RU 2013130002A RU 2013130002/10 A RU2013130002/10 A RU 2013130002/10A RU 2013130002 A RU2013130002 A RU 2013130002A RU 2013130002 A RU2013130002 A RU 2013130002A
Authority
RU
Russia
Prior art keywords
seq
antibody
apoe
amino acid
atcc
Prior art date
Application number
RU2013130002/10A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид ХОЛЬТЦМАН
Джунгсу КИМ
Хун ЦЗЯН
Адам ЭЛТОРЕЙ
Original Assignee
Дзе Вашингтон Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Вашингтон Юниверсити filed Critical Дзе Вашингтон Юниверсити
Publication of RU2013130002A publication Critical patent/RU2013130002A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2013130002/10A 2010-12-02 2011-12-02 Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками RU2013130002A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US61/419,060 2010-12-02
US201161548542P 2011-10-18 2011-10-18
US61/548,542 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number Publication Date
RU2013130002A true RU2013130002A (ru) 2015-01-10

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013130002/10A RU2013130002A (ru) 2010-12-02 2011-12-02 Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками

Country Status (14)

Country Link
US (2) US20140037638A1 (enExample)
EP (1) EP2646053A4 (enExample)
JP (1) JP2014502276A (enExample)
KR (1) KR20140017513A (enExample)
CN (1) CN103338786A (enExample)
AU (1) AU2011336360A1 (enExample)
BR (1) BR112013013723A2 (enExample)
CA (1) CA2819679A1 (enExample)
MX (1) MX2013006116A (enExample)
NZ (1) NZ611614A (enExample)
RU (1) RU2013130002A (enExample)
SG (1) SG190952A1 (enExample)
WO (1) WO2012075422A2 (enExample)
ZA (1) ZA201303996B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US10830775B2 (en) 2014-09-30 2020-11-10 Washington University Tau kinetic measurements
WO2017192711A1 (en) * 2016-05-03 2017-11-09 University Of South Florida Compositions and methods of modulating abeta protein
US11124562B2 (en) 2016-10-28 2021-09-21 Washington University Anti-ApoE antibodies
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
AU2020282792B2 (en) * 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
WO2023069892A1 (en) * 2021-10-19 2023-04-27 Short Jay M Conditionally active proteins for neurodegenerative diseases
JP2025540077A (ja) * 2022-11-30 2025-12-11 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ナチュラルキラー細胞エンゲージャー
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009155A1 (en) * 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
GB2408508A (en) * 2003-11-28 2005-06-01 Astrazeneca Ab Apolipoprotein antibodies
AU2005228764A1 (en) * 2004-03-30 2005-10-13 Renomedix Institute Inc. Remedy for prion disease and method of producing the same
WO2007098417A2 (en) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2011109246A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Also Published As

Publication number Publication date
ZA201303996B (en) 2015-10-28
NZ611614A (en) 2015-07-31
US20140037638A1 (en) 2014-02-06
US20160355581A1 (en) 2016-12-08
EP2646053A4 (en) 2014-05-28
WO2012075422A2 (en) 2012-06-07
MX2013006116A (es) 2013-10-17
JP2014502276A (ja) 2014-01-30
CN103338786A (zh) 2013-10-02
WO2012075422A3 (en) 2012-10-04
SG190952A1 (en) 2013-07-31
AU2011336360A1 (en) 2013-07-04
CA2819679A1 (en) 2012-06-07
BR112013013723A2 (pt) 2019-09-24
KR20140017513A (ko) 2014-02-11
EP2646053A2 (en) 2013-10-09

Similar Documents

Publication Publication Date Title
AU2018255221B2 (en) Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
RU2760875C1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
AU2011329647B2 (en) Neutralizing anti-CCL20 antibodies
JP2014502276A5 (enExample)
Antonios et al. Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
RU2012141556A (ru) Способы и композиции для лечения болезни дего
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
RU2017137872A (ru) Композиции для ингибирования masp-2-зависимой активации комплемента
JP2009530423A5 (enExample)
RU2008137764A (ru) Способы предотвращения и лечения амилоидных заболеваний
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
RU2015143886A (ru) Антитела к тау и способы применения
JP2009530299A5 (enExample)
WO2005103083A8 (en) Anti-cd38 human antibodies and uses therefor
JP2014524733A5 (enExample)
RS59557B1 (sr) Tau antitela i njihova upotreba
RU2015118180A (ru) Антитела к бета-амилоиду
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
CN113508131B (zh) 人源化抗Aβ单克隆抗体及其应用
RU2010150754A (ru) АНТИТЕЛА ПРОТИВ PirB
WO2023143425A1 (zh) 改善认知障碍的方法
JP2014509860A5 (enExample)
Sehlin et al. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-Aβ antibodies
WO2021242493A2 (en) Compositions and methods for treating epilepsy

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20161114